MacroGenics, Inc. (MGNX)

Market Cap	107.88M
Revenue (ttm)	154.05M
Net Income (ttm)	-55.81M
Shares Out	63.09M
EPS (ttm)	-0.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	516,104
Open	1.780
Previous Close	1.780
Day's Range	1.670 - 1.780
52-Week Range	0.990 - 5.770
Beta	1.59
Analysts	Hold
Price Target	5.33 (+211.7%)
Earnings Date	Aug 5, 2025

About MGNX

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 10, 2013
• Employees: 341
• Stock Exchange: NASDAQ
• Ticker Symbol: MGNX
• Website: https://www.macrogenics.com

Financial Performance

In 2024, MacroGenics's revenue was $149.96 million, an increase of 155.26% compared to the previous year's $58.75 million. Losses were -$66.97 million, 639.3% more than in 2023.

Analyst Summary

According to 9 analysts, the average rating for MGNX stock is "Hold." The 12-month stock price target is $5.33, which is an increase of 211.70% from the latest price.

Price Target

$5.33

(211.70% upside)

Analyst Consensus: Hold